Elise Kayson
Overview
Explore the profile of Elise Kayson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
568
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frank S, Testa C, Goldstein J, Kayson E, Leavitt B, Oakes D, et al.
CNS Drugs
. 2025 Jan;
39(2):185-195.
PMID: 39825184
Background: Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose...
2.
Anderson K, Arbatti L, Hosamath A, Feigin A, Goldstein J, Kayson E, et al.
J Huntingtons Dis
. 2024 May;
13(2):237-248.
PMID: 38701155
Background: Direct-to-participant online reporting facilitates the conduct of clinical research by increasing access and clinically meaningful patient engagement. Objective: We assessed feasibility of online data collection from adults with diagnosed...
3.
Furr Stimming E, Claassen D, Kayson E, Goldstein J, Mehanna R, Zhang H, et al.
Lancet Neurol
. 2023 May;
22(6):494-504.
PMID: 37210099
Background: Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of tardive dyskinesia. To address the ongoing need for improved symptomatic treatments for individuals with...
4.
Frank S, Testa C, Edmondson M, Goldstein J, Kayson E, Leavitt B, et al.
CNS Drugs
. 2022 Oct;
36(11):1207-1216.
PMID: 36242718
Background: Deutetrabenazine is approved in the USA, China, Australia, Israel, Brazil, and South Korea for the treatment of chorea associated with Huntington disease. Objective: We aimed to evaluate the long-term...
5.
Schneider R, Omberg L, Macklin E, Daeschler M, Bataille L, Anthwal S, et al.
Ann Clin Transl Neurol
. 2020 Dec;
8(2):308-320.
PMID: 33350601
Objective: The expanding power and accessibility of personal technology provide an opportunity to reduce burdens and costs of traditional clinical site-centric therapeutic trials in Parkinson's disease and generate novel insights....
6.
Kayson E, Eberly S, Anderson K, Marder K, Shoulson I, Oakes D, et al.
J Huntingtons Dis
. 2019 Aug;
8(4):435-441.
PMID: 31381523
Background: There is limited understanding of the feasibility of conducting long-term research among undiagnosed (pre-symptomatic) adults at risk to develop Huntington disease (HD), while protecting their emotional well-being and safety....
7.
Shoulson I, Eberly S, Oakes D, Kayson E, Young A
Ann Clin Transl Neurol
. 2019 Jun;
6(6):1046-1052.
PMID: 31211168
Objective: To examine phenotype-genotype discrepancies (PGDs) wherein genotype-concealed and prospective judgments of the motor onset of Huntington disease (HD) occurred among at-risk adults who had nonexpanded (<37) cytosine-adenine-guanine (CAG) trinucleotide...
8.
Anderson K, Eberly S, Marder K, Oakes D, Kayson E, Young A, et al.
Clin Genet
. 2019 May;
96(1):28-34.
PMID: 31093973
Rates of genetic testing in Huntington disease (HD) are lower than was predicted before direct DNA testing became available. Clinicians often do not have in-depth conversations with people at risk...
9.
Frank S, Stamler D, Kayson E, Claassen D, Colcher A, Davis C, et al.
JAMA Neurol
. 2017 Jul;
74(8):977-982.
PMID: 28692723
Importance: Tetrabenazine is efficacious for chorea control; however, tolerability concerns exist. Deutetrabenazine, a novel molecule that reduces chorea, was well tolerated in a double-blind, placebo-controlled study. Objectives: To evaluate the...
10.
Anderson K, Eberly S, Groves M, Kayson E, Marder K, Young A, et al.
J Huntingtons Dis
. 2016 Dec;
5(4):389-394.
PMID: 27983561
Background: Suicidal ideation (SI) and attempts are increased in Huntington's disease (HD), making risk factor assessment a priority. Objective: To determine whether, hopelessness, irritability, aggression, anxiety, CAG expansion status, depression,...